The cost-effectiveness of biologics for the treatment of rheumatoid arthritis: A systematic review

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Joensuu, Jaana T ^a   Huoponen, Saara ^a   Aaltonen, Kalle J ^a   Konttinen, Yrjö T ^a,b   Nordström, Dan ^a,b   Blom, Marja ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; RITUXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT;

COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; HUMAN; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; SYSTEMATIC REVIEW; ARTHRITIS, RHEUMATOID; COST BENEFIT ANALYSIS; ECONOMICS; META ANALYSIS;

SCOPUS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; COST-BENEFIT ANALYSIS; HUMANS;

EID: 84924975759     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0119683     Document Type: Review

References (56)

1. Alamanos Y, Voulgari PV, Drosos AA. Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review. Semin Arthritis Rheum. 2006; 36: 182-188. PMID: 17045630
2. Lundkvist J, Kastäng F, Kobelt G. The burden of rheumatoid arthritis and access to treatment: health burden and costs. Eur J Health Econ. 2008; 8: S49-60. PMID: 18157732
3. Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014; 73: 492-509. doi: 10.1136/annrheumdis-2013-204573 PMID: 24161836
4. Aaltonen KJ, Virkki LM, Malmivaara A, Konttinen YT, Nordström DC, Blom M. Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. PLoS One. 2012; 7: e30275. doi: 10.1371/journal.pone.0030275 PMID: 22272322
5. Nam JL, Winthrop KL, van Vollenhoven RF, Pavelka K, Valesini G, Hensor EM a, et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis. 2010; 69: 976-986. doi: 10.1136/ard.2009.126573 PMID: 20447957
6. Nam JL, Ramiro S, Gaujoux-Viala C, Takase K, Leon-Garcia M, Emery P, et al. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2014; 73: 516-528. doi: 10.1136/annrheumdis-2013-204577 PMID: 24399231
7. rd ed. New York: Oxford University Press; 2005. PMID: 15693028
8. Schoels M, Wong J, Scott DL, Zink A, Richards P, Landewé R, et al. Economic aspects of treatment options in rheumatoid arthritis: A systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2010; 69: 995-1003. doi: 10.1136/ard.2009.126714 PMID: 20447950
9. Tsao NW, Bansback NJ, Shojania K, Marra C a. The issue of comparators in economic evaluations of biologic response modifiers in rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2012; 26: 659-676. doi: 10.1016/j.berh.2012.07.012 PMID: 23218430
10. Van der Velde G, Pham B, Machado M, Ieraci L, Witteman W, Bombardier C, et al. Cost-effectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: a systematic review. Arthritis Care Res(Hoboken). 2011; 63: 65-78. doi: 10.1002/acr.20338 PMID: 20740606
11. Shemilt I, Mugford M, Byford S, Drummond M, Eisenstein E, Knapp M, et al. Incorporating economics evidence. In: Higgins JP, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Collaboration; 2008. pp. 449-479. doi: 10.1002/14651858.CD004741.pub2 PMID: 18843668
12. Drummond M, Jefferson T. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ. 1996; 313: 275-283. PMID: 8704542
13. Philips Z, Ginnelly L, Sculpher M, Claxton K. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol Assess. 2004; 8: 1-172. PMID: 15546515
14. Spalding JR, Hay J. Cost effectiveness of tumour necrosis factor-α inhibitors as first-line agents in rheumatoid arthritis. Pharmacoeconomics. 2006; 24: 1221-1232. PMID: 17129076
15. Brennan A, Bansback N, Nixon R, Madan J, Harrison M, Watson K, et al. Modelling the cost effectiveness of TNF-α antagonists in the management of rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Registry. Rheumatology(Oxford). 2007; 46: 1345-1354. PMID: 17562686
16. Kobelt G, Eberhardt K, Geborek P. TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: Costs and outcomes in a follow up study of patients with Ra treated with etanercept or infliximab in southern Sweden. Ann Rheum Dis. 2004; 63: 4-10. PMID: 14672883
17. Vera-Llonch M, Massarotti E, Wolfe F, Shadick N, Westhovens R, Sofrygin O, et al. Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate. Rheumatology (Oxford). 2008; 47: 535-541. doi: 10.1093/rheumatology/ken007 PMID: 18356179
18. Merkesdal S, Kirchhoff T, Wolka D, Ladinek G, Kielhorn A, Rubbert-Roth A. Cost-effectiveness analysis of rituximab treatment in patients in Germany with rheumatoid arthritis after etanercept-failure. Eur J Health Econ. 2010; 11: 95-104. doi: 10.1007/s10198-009-0205-y PMID: 19967426
19. Van Den Hout WB, Goekoop-Ruiterman YPM, Allaart CF, Vries-Bouwstra JKD, Hazes JMM, Kerstens PJSM, et al. Cost-utility analysis of treatment strategies in patients with recent-onset rheumatoid arthritis. Arthritis Care Res(Hoboken). 2009; 61: 291-299.
20. Soini EJ, Puolakka K, Vihervaara V, Kauppi MJ. Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis. J Med Econ. 2012; 15: 340-51. doi: 10.3111/13696998.2011.649327 PMID: 22168785
21. Davies A, Cifaldi MA, Segurado OG, Weisman MH. Cost-effectiveness of sequential therapy with tumor necrosis factor antagonists in early rheumatoid arthritis. J Rheumatol. 2009; 36: 16-25. doi: 10.3899/jrheum.080257 PMID: 19012363
22. Clark W, Jobanputra P, Barton P, Burls A. The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis. Health Technol Assess. 2004; 8: 1-117. PMID: 15546515
23. Welsing PMJ, Severens JL, Hartman M, van Riel PLCM, Laan RFJM. Modeling the 5-year cost effectiveness of treatment strategies including tumor necrosis factor-blocking agents and leflunomide for treating rheumatoid arthritis in the Netherlands. Arthritis Care Res(Hoboken). 2004; 51: 964-973.
24. Nguyen CM, Bounthavong M, Mendes MAS, Christopher MLD, Tran JN, Kazerooni R, et al. Cost Utility of Tumour Necrosis Factor- a Inhibitors for Rheumatoid Arthritis. Pharmacoeconomics. 2012; 30: 575-593. doi: 10.2165/11594990-000000000-00000 PMID: 22640174
25. Lekander I, Borgström F, Lysholm J, van Vollenhoven RF, Lindblad S, Geborek P, et al. The cost-effectiveness of TNF-inhibitors for the treatment of rheumatoid arthritis in Swedish clinical practice. Eur J Health Econ. 2013; 14: 863-873. doi: 10.1007/s10198-012-0431-6 PMID: 22990378
26. Lekander I, Borgstrm F, Svarvar P, Ljung T, Carli C, Van Vollenhoven RF. Cost-effectiveness of real-world infliximab use in patients with rheumatoid arthritis in Sweden. Int J Technol Assess Health Care. 2010; 26: 54-61. doi: 10.1017/S0266462309990596 PMID: 20059781
27. Finckh A, Bansback N, Marra CA, Anis AH, Michaud K, Lubin S, et al. Treatment of Very Early Rheumatoid Arthritis With Symptomatic Therapy, Disease-Modifying Antirheumatic Drugs, or Biologic Agents: A Cost-Effectiveness Analysis. Ann Intern Med. 2009; 151: 612-621. doi: 10.7326/0003-4819-151-9-200911030-00006 PMID: 19884622
28. Chen Y-F, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess. 2006; 10: 1-248. PMID: 17134596
29. Wu B, Wilson A, Wang F-f., Wang S-l., Wallace DJ, Weisman MH, et al. Cost Effectiveness of Different Treatment Strategies in the Treatment of Patients with Moderate to Severe Rheumatoid Arthritis in China. PLoS One. 2012; 7: e47373. doi: 10.1371/journal.pone.0047373 PMID: 23056637
30. Schipper LG, Kievit W, den Broeder AA, van der Laar MA, Adang EMM, Fransen J, et al. Treatment strategies aiming at remission in early rheumatoid arthritis patients: Starting with methotrexate monotherapy is cost-effective. Rheumatology (Oxford). 2011; 50: 1320-1330. doi: 10.1093/rheumatology/ker084 PMID: 21371999
31. Kielhorn A, Porter D, Diamantopoulos A, Lewis G. UK cost-utility analysis of rituximab in patients with rheumatoid arthritis that failed to respond adequately to a biologic disease-modifying antirheumatic drug. Curr Med Res Opin. 2008; 24: 2639-50. doi: 10.1185/03007990802321683 PMID: 18687164
32. Jobanputra P, Barton P, Bryan S, Burls A. The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: A systematic review and economic evaluation. Health Technol Assess. 2002; 6: 1-110.
33. Diamantopoulos A, Benucci M, Capri S, Berger W, Wintfeld N, Giuliani G, et al. Economic evaluation of tocilizumab combination in the treatment of moderate-to-severe rheumatoid arthritis in Italy. J Med Econ. 2012; 15: 576-585. doi: 10.3111/13696998.2012.665110 PMID: 22313326
34. Brodszky V, Orlewska E, Péntek M, Kárpáti K, Skoupá J, Gulacsi L. Challenges in economic evaluation of new drugs: Experience with rituximab in Hungary. Med Sci Monit. 2010; 16: 1-5. PMID: 20190692
35. Tanno M, Nakamura I, Ito K, Tanaka H, Ohta H, Kobayashi M, et al. Modeling and cost-effectiveness analysis of etanercept in adults with rheumatoid arthritis in Japan: A preliminary analysis. Mod Rheumatol. 2006; 16: 77-84. PMID: 16633926
36. Kobelt G, Lindgren P, Singh A, Klareskog L. Cost effectiveness of etanercept(Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial. Ann Rheum Dis. 2005; 64: 1174-1179. PMID: 15708879
37. Farahani P, Levine M, Goeree R. A comparison between integrating clinical practice setting and randomized controlled trial setting into economic evaluation models of therapeutics. J Eval Clin Pract. 2006; 12: 463-470. PMID: 16907691
38. Kobelt G, Lekander I, Lang A, Raffeiner B, Botsios C, Geborek P. Cost-effectiveness of etanercept treatment in early active rheumatoid arthritis followed by dose adjustment. Int J Technol Assess Health Care. 2011; 27: 193-200. doi: 10.1017/S0266462311000195 PMID: 21736857
39. Wong JB, Singh G, Kavanaugh A. Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis. Am J Med. 2002; 113: 400-408. PMID: 12401535
40. Wailoo AJ, Bansback N, Brennan A, Michaud K, Nixon RM, Wolfe F. Biologic drugs for rheumatoid arthritis in the Medicare program: a cost-effectiveness analysis. Arthritis Rheum. 2008; 58: 939-46. doi: 10.1002/art.23374 PMID: 18383356
41. Bansback NJ, Brennan A, Ghatnekar O. Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden. Ann Rheum Dis. 2005; 64: 995-1002. PMID: 15550533
42. Yuan Y, Trivedi D, Maclean R, Rosenblatt L. Indirect cost-effectiveness analyses of abatacept and rituximab in patients with moderate-to-severe rheumatoid arthritis in the United States. J Med Econ. 2010; 13: 33-41. doi: 10.3111/13696990903508021 PMID: 20001596
43. Vera-Llonch M, Massarotti E, Wolfe F, Westhovens R, Sofrygin O, Maclean R, et al. Cost-Effectiveness of Abatacept in Patients with Moderately to Severely Active Rheumatoid Arthritis and Inadequate Response to Tumor Necrosis Factor- α Antagonists. J Rheumatol. 2008; 35: 1745-1753. PMID: 18634164
44. Marra CA, Marion SA, Guh DP, Najafzadeh M, Wolfe F, Esdaile JM, et al. Not all "quality-adjusted life years" are equal. J Clin Epidemiol. 2007; 60: 616-624. PMID: 17493521
45. Lindgren P, Geborek P, Kobelt G. Modeling the cost-effectiveness of treatment of rheumatoid arthritis with rituximab using registry data from Southern Sweden. Int J Technol Assess Health Care. 2009; 25: 181-189. doi: 10.1017/S0266462309090230 PMID: 19331709
46. Coyle D, Judd M, Blumenauer B, Cranney A, Tugwell P, Well GA. Infliximab and Etanercept in Patients with Rheumatoid Arthritis: A Systematic Review and Economic Evaluation [Technology report no 64]. Ottawa: Canadian Coordinating Office for Health Technology Assessment. 2006. Available: http://www.cadth.ca/en/products/health-technology-assessment/publication/610. Accessed 4 February 2015.
47. Chiou C-F, Choi J, Reyes CM. Cost-effectiveness analysis of biological treatments for rheumatoid arthritis. Expert Rev Pharmacoecon Outcomes Res. 2004; 4: 307-315. doi: 10.1586/14737167.4.3.307 PMID: 19807313
48. Canadian Agency for Drugs and Technologies in Health. Clinical and Economic Overview: Biological Response Modifier Agents for Adults with Rheumatoid Arthritis. CADTH Therapeutic Review. 2010. Available: http://www.cadth.ca/media/pdf/TR-RA-Clinical-and-Economic-Overview-e.pdf. Accessed 4 February 2015.
49. Brennan A, Bansback N, Reynolds A, Conway P. Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK. Rheumatology(Oxford). 2004; 43: 62-72. PMID: 12890861
50. Barton P, Jobanputra P, Wilson J, Bryan S, Burls A. The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis. Health Technol Assess. 2004; 8: 1-104. PMID: 15546515
51. Barbieri M, Wong JB, Drummond M. The cost effectiveness of infliximab for severe treatment-resistant rheumatoid arthritis in the UK. Pharmacoeconomics. 2005; 23: 607-618. PMID: 15960556
52. Kobelt G, Jönsson L, Young A, Eberhardt K. The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study. Rheumatology(Oxford). 2003; 42: 326-335. PMID: 12595631
53. Malottki K, Barton P, Tsourapas A, Uthman AO, Liu Z, Routh K, et al. Adalimumab, etanercept, infiximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: A systematic review and economic evaluation. Health Technol Assess. 2011; 15: 1-278.
54. Hallinen TA, Soini EJ, Eklund K, Puolakka K. Cost-utility of different treatment strategies after the failure of tumour necrosis factor inhibitor in rheumatoid arthritis in the Finnish setting. Rheumatology(Oxford). 2010; 49: 767-777. doi: 10.1093/rheumatology/kep425 PMID: 20100793
55. National Institution for Health and Clinical Excellence. Guide to the methods of technology appraisal 2013. 2013. Available: http://publications.nice.org.uk/pmg9. Accessed 4 February 2015.
56. Hoaglin DC, Hawkins N, Jansen JP, Scott D a, Itzler R, Cappelleri JC, et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. Value Health. 2011; 14: 429-437. doi: 10.1016/j.jval.2011.01.011 PMID: 21669367